5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients

Prostate cancer treatment has quietly changed a lot in five years. If you or someone you love is living with it, it helps to know not just that things have improved, but how — because the pattern behind these changes is the best clue we have for what's coming next. Here's the story, year by year, told partly through doctors and patients CURE has interviewed along the way.

The Big Picture: How Prostate Cancer Treatment Has Changed Since 2021

Five years ago, Pluvicto — a treatment that delivers radiation straight to prostate cancer cells — was brand new, and only available as a last resort after chemo had already failed. Today, that same treatment is approved as soon as cancer is found to have spread, before chemo is ever needed. That's the whole five-year story in miniature: "last resort" treatments keep moving earlier, once they prove they work.

2021: A New Kind of Scan Changes How Doctors Find Prostate Cancer

Pylarify (piflufolastat F-18), a new kind of imaging called PSMA PET, let doctors find recurring or spreading prostate cancer earlier and more accurately than older scans could — even when PSA levels were still low. This might not sound as exciting as a new drug, but it mattered enormously: it's the scan doctors now use to decide who qualifies for the newer treatments described below. Illuccix (kit for the preparation of gallium Ga 68 gozetotide), a second PSMA imaging agent, followed later that year, making this kind of scan more widely available.

2022: Pluvicto Gets Approved, and Nubeqa (Darolutamide) Shows a Major Survival Benefit

Pluvicto (lutetium Lu-177 vipivotide tetraxetan), the first PSMA-targeted radioactive treatment, was approved — but only for men whose cancer had already spread and stopped responding to chemotherapy. Dr. Richard Wahl, president of the Society of Nuclear Medicine and Molecular Imaging, told CURE that "this therapy is truly a targeted therapy. The radioactive Lu-177 molecules that are a part of Pluvicto (hone) into the tumors." He was also honest about its limits, noting it "prolongs survival" but "is not curative of the disease, which means that more research is needed."

The same year, adding Nubeqa (darolutamide) to standard hormone therapy and chemo showed a major benefit in newly diagnosed metastatic prostate cancer, in the ARASENS trial. Dr. Maha Hussain of Northwestern University's Feinberg School of Medicine told CURE the combination "should be considered a new standard of care of patients with metastatic hormone sensitive prostate cancer," noting it cut the risk of death by about 32% — and that so many patients were still alive at the data cutoff, researchers couldn't even calculate an average survival time yet.

2023: Prostate Cancer Becomes a Genetically Personalized Disease

Three new drug combinations were approved in a single year, each matched to a specific genetic mutation — meaning treatment could finally be tailored to a man's own tumor genetics, not just a one-size-fits-all approach:

• Lynparza (olaparib) plus Zytiga (abiraterone) — for men with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). In the PROpel trial, this combination extended median survival to 42.1 months, compared to 34.7 months with Zytiga alone.
• Zejula (niraparib) plus Zytiga (abiraterone) — a second option specifically for BRCA1/2-mutated mCRPC.
• Talzenna (talazoparib) plus Xtandi (enzalutamide) — for the broader group of men with HRR gene-mutated mCRPC, based on the TALAPRO-2 trial, which found a 55% reduction in the risk of the cancer getting worse or death.

Dr. Rohan Garje summed up the shift well in an interview: before this, men mostly had single PARP-inhibitor pills as options. "Now we have combination options with PARP inhibitors, specifically with enzalutamide and talazoparib, and there's a combination therapy approved for olaparib [with] abiraterone acetate and also niraparib with abiraterone. This is definitely exciting."

2024: Real-World Data Confirms the Benefit

2024 didn't bring a new approval, but it brought something almost as important: proof that the 2022 survival benefit held up outside a controlled trial. Follow-up data from the ARASENS trial, presented at the 2024 ASCO Genitourinary Cancers Symposium, showed the Nubeqa combination also lowered hospitalization rates for men with metastatic hormone-sensitive prostate cancer, compared with placebo. That matters beyond the headline survival number — fewer hospital stays means more time at home, not just more time alive, and it's the kind of quality-of-life confirmation that a purely survival-focused trial result doesn't capture on its own.

2025: Pluvicto Moves Earlier, Before Chemo Is Ever Needed

Pluvicto's approval expanded to cover men with mCRPC before they'd tried chemotherapy — nearly tripling the number of men who could benefit from it. Dr. Malay Rao, a radiation oncologist, told CURE that Pluvicto's side effects — mainly fatigue, loss of appetite, and some drops in blood counts — are generally milder than what chemotherapy causes, which matters even more now that it's reaching men earlier in their treatment course, when quality of life considerations weigh even more heavily.

2026: Pluvicto and Nubeqa Both Reach the Earliest Point of Metastatic Diagnosis

Pluvicto's approval expanded again — this time to men whose cancer has just spread but is still responding to hormone therapy, the earliest point at which metastatic prostate cancer is typically found. In four years, Pluvicto went from "only after chemo has failed" to "as soon as we find out it's spread." Nubeqa picked up a similar earlier-use approval around the same time, based on the ARANOTE trial, continuing the same "move it earlier" pattern that's defined this entire five-year stretch.

Does Any of This Actually Help Men Live Longer?

Yes. Among men with metastatic prostate cancer specifically, five-year survival has climbed steadily:

• 29% for men diagnosed in 2010
• 35% for men diagnosed in 2015
• 43% for men diagnosed in 2021

That's a real, measurable improvement, and it lines up directly with the treatments described above becoming available.

The Honest Part: Not Everyone Is Benefiting Equally, and Here's Why

This is worth understanding clearly, because it's a different kind of problem than "we need a better drug." Overall, the U.S. prostate cancer death rate isn't falling nearly as fast as it used to — it dropped 3.5% a year in the 1990s and 2000s, but only about 0.6% a year over the last decade, and lately it's basically flat.

That's not because the newer treatments above aren't working — they are. It's because more men are being diagnosed after their cancer has already spread, rather than being caught early. Once diagnosed at that later stage, men are living longer than they used to, thanks to the treatments above — but fewer men are getting caught in time to avoid reaching that stage at all. The treatments are doing their job. Screening and early detection are the piece that hasn't kept pace.

What this means practically: regular PSA screening and talking to your doctor about your personal risk factors matters just as much as knowing about new treatments — maybe more, since catching prostate cancer early still gives you the best odds by far.

What This Means Now: Where Prostate Cancer Treatment Is Headed Next

Here's what's specifically, concretely next for prostate cancer — not speculation, but a real trial already underway:

A Phase 3 trial is already testing whether Nubeqa (darolutamide) can work even before cancer shows up as metastatic on a standard scan. The ARASTEP trial (NCT05794906) is enrolling 970 patients globally right now, testing Nubeqa plus hormone therapy against hormone therapy alone in men with high-risk biochemical recurrence — meaning their PSA is rising after initial treatment, and a PSMA PET scan has found a suspicious spot, but standard imaging still shows nothing. If it works, that would push Nubeqa's use even earlier than its current 2026 approval, into cancer that hasn't been confirmed as metastatic by conventional scans at all. This is a real, registered, actively enrolling trial — not a hope for the future.

The PARP-inhibitor approvals already on the books are the concrete evidence for personalized treatment, not a prediction. Lynparza plus Zytiga, Zejula plus Zytiga, and Talzenna plus Xtandi are three separate, already-approved combinations, each tied to a specific genetic mutation. That fragmentation by biomarker has already happened; it isn't a forecast.

The screening gap is the one place where the honest answer is "this needs to change," not "this is already changing." There's no dated trial or approval that fixes advanced-stage diagnosis at first presentation — that's a public health and screening problem, not something in a drug pipeline right now.

Questions worth asking your doctor:

• Has my cancer been tested for BRCA or other DNA-repair gene mutations?
• Am I a candidate for PSMA PET imaging to check for spread more precisely than older scans?
• If a treatment like Pluvicto wasn't an option for me before, has that changed with the newer approvals?

If you're currently on a treatment that started out approved only for advanced, heavily pretreated disease, this five-year record is a real reason for hope — it's happened this way more than once, not by luck. And if you have loved ones who haven't been getting regular PSA screening, this is a good moment to bring it up. The treatments keep getting better for men whose cancer is caught after it's spread. But catching it before that point is still the single biggest factor in a good outcome, and that part is in your hands.

Advice for the Road Ahead

Prostate cancer survivor Ronald Wakefield offered CURE this advice for the newly diagnosed: "Don't let that stop you from seeking treatment. Go seek treatment, take care of yourself. And then there are other things, ways you can deal with whatever you're faced with, after that." Fellow survivor Ernie Strauss echoed the sentiment, drawing on his own experience going through radiation while his father was treated for prostate cancer at the same time.

For people newly diagnosed with prostate cancer, their experiences offer a simple but important message: take things one step at a time, seek out the care you need and remember that you don't have to navigate the experience alone. Treatment can be challenging, but connecting with your health care team, loved ones and other people who have been through prostate cancer can help make the journey feel more manageable.

While every person's diagnosis and treatment experience is different, the perspective of survivors like Wakefield and Strauss can serve as a reminder that there is life beyond a prostate cancer diagnosis and support is available along the way.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.